Tunlametinib — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase4	Phase 4	6	6	1	14	0	—	—	Sep 1, 2017
Malignant Lung Neoplasm	Phase1	Phase 1	0	0	0	1	0	—	—	May 21, 2020

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF Fusion1
BRAF Inhibitor + Tunlametinib

Clinical trials

Trials with this intervention (14)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–14 of 14 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07750067	Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma	recruiting	Phase 2	37	Sun Yat-sen UniversityOTHER	1	Aug 10, 2026	clinicaltrials
NCT07445022	RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma	recruiting	Phase 4	110	Fudan University